Economic evaluation of smoking cessation in Ontario's regional cancer programs

Sandjar Djalalov, Lisa Masucci, Wanrudee Isaranuwatchai, William Evans, Alice Peter, Rebecca Truscott, Erin Cameron, Nicole Mittmann, Linda Rabeneck, Kelvin Chan, Jeffrey S Hoch

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Quitting smoking after a diagnosis of cancer results in greater response to treatment and decreased risk of disease recurrence and second primary cancers. The objective of this study was to evaluate the potential cost-effectiveness of two smoking cessation approaches: the current basic smoking cessation program consisting of screening for tobacco use, advice, and referral; and a best practice smoking cessation program that includes the current basic program with the addition of pharmacological therapy, counseling, and follow-up. A Markov model was constructed that followed 65-year-old smokers with cancer over a lifetime horizon. Transition probabilities and mortality estimates were obtained from the published literature. Costs were obtained from standard costing sources in Ontario and reports. Probabilistic and deterministic sensitivity analyses were conducted to address parameter uncertainties. For smokers with cancer, the best practice smoking cessation program was more effective and more costly than the basic smoking cessation program. The incremental cost-effectiveness ratio of the best practice smoking cessation program compared to the basic smoking cessation program was $3367 per QALY gained and $5050 per LY gained for males, and $2050 per QALY gained and $4100 per LY gained for females. Results were most sensitive to the hazard ratio of mortality for former and current smokers, the probability of quitting smoking through participation in the program and smoking-attributable costs. The study results suggested that a best practice smoking cessation program could be a cost-effective option. These findings can support and guide implementation of smoking cessation programs.

Original languageEnglish (US)
JournalCancer Medicine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Ontario
Smoking Cessation
Cost-Benefit Analysis
Practice Guidelines
Neoplasms
Quality-Adjusted Life Years
Smoking
Costs and Cost Analysis
Second Primary Neoplasms
Mortality
Tobacco Use
Uncertainty
Counseling
Referral and Consultation
Pharmacology
Recurrence

Keywords

  • Cost-effectiveness
  • Oncology
  • Smoking cessation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Djalalov, S., Masucci, L., Isaranuwatchai, W., Evans, W., Peter, A., Truscott, R., ... Hoch, J. S. (Accepted/In press). Economic evaluation of smoking cessation in Ontario's regional cancer programs. Cancer Medicine. https://doi.org/10.1002/cam4.1495

Economic evaluation of smoking cessation in Ontario's regional cancer programs. / Djalalov, Sandjar; Masucci, Lisa; Isaranuwatchai, Wanrudee; Evans, William; Peter, Alice; Truscott, Rebecca; Cameron, Erin; Mittmann, Nicole; Rabeneck, Linda; Chan, Kelvin; Hoch, Jeffrey S.

In: Cancer Medicine, 01.01.2018.

Research output: Contribution to journalArticle

Djalalov, S, Masucci, L, Isaranuwatchai, W, Evans, W, Peter, A, Truscott, R, Cameron, E, Mittmann, N, Rabeneck, L, Chan, K & Hoch, JS 2018, 'Economic evaluation of smoking cessation in Ontario's regional cancer programs', Cancer Medicine. https://doi.org/10.1002/cam4.1495
Djalalov S, Masucci L, Isaranuwatchai W, Evans W, Peter A, Truscott R et al. Economic evaluation of smoking cessation in Ontario's regional cancer programs. Cancer Medicine. 2018 Jan 1. https://doi.org/10.1002/cam4.1495
Djalalov, Sandjar ; Masucci, Lisa ; Isaranuwatchai, Wanrudee ; Evans, William ; Peter, Alice ; Truscott, Rebecca ; Cameron, Erin ; Mittmann, Nicole ; Rabeneck, Linda ; Chan, Kelvin ; Hoch, Jeffrey S. / Economic evaluation of smoking cessation in Ontario's regional cancer programs. In: Cancer Medicine. 2018.
@article{fc0e5bafc5d2419da11330512fa34ba2,
title = "Economic evaluation of smoking cessation in Ontario's regional cancer programs",
abstract = "Quitting smoking after a diagnosis of cancer results in greater response to treatment and decreased risk of disease recurrence and second primary cancers. The objective of this study was to evaluate the potential cost-effectiveness of two smoking cessation approaches: the current basic smoking cessation program consisting of screening for tobacco use, advice, and referral; and a best practice smoking cessation program that includes the current basic program with the addition of pharmacological therapy, counseling, and follow-up. A Markov model was constructed that followed 65-year-old smokers with cancer over a lifetime horizon. Transition probabilities and mortality estimates were obtained from the published literature. Costs were obtained from standard costing sources in Ontario and reports. Probabilistic and deterministic sensitivity analyses were conducted to address parameter uncertainties. For smokers with cancer, the best practice smoking cessation program was more effective and more costly than the basic smoking cessation program. The incremental cost-effectiveness ratio of the best practice smoking cessation program compared to the basic smoking cessation program was $3367 per QALY gained and $5050 per LY gained for males, and $2050 per QALY gained and $4100 per LY gained for females. Results were most sensitive to the hazard ratio of mortality for former and current smokers, the probability of quitting smoking through participation in the program and smoking-attributable costs. The study results suggested that a best practice smoking cessation program could be a cost-effective option. These findings can support and guide implementation of smoking cessation programs.",
keywords = "Cost-effectiveness, Oncology, Smoking cessation",
author = "Sandjar Djalalov and Lisa Masucci and Wanrudee Isaranuwatchai and William Evans and Alice Peter and Rebecca Truscott and Erin Cameron and Nicole Mittmann and Linda Rabeneck and Kelvin Chan and Hoch, {Jeffrey S}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/cam4.1495",
language = "English (US)",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Economic evaluation of smoking cessation in Ontario's regional cancer programs

AU - Djalalov, Sandjar

AU - Masucci, Lisa

AU - Isaranuwatchai, Wanrudee

AU - Evans, William

AU - Peter, Alice

AU - Truscott, Rebecca

AU - Cameron, Erin

AU - Mittmann, Nicole

AU - Rabeneck, Linda

AU - Chan, Kelvin

AU - Hoch, Jeffrey S

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Quitting smoking after a diagnosis of cancer results in greater response to treatment and decreased risk of disease recurrence and second primary cancers. The objective of this study was to evaluate the potential cost-effectiveness of two smoking cessation approaches: the current basic smoking cessation program consisting of screening for tobacco use, advice, and referral; and a best practice smoking cessation program that includes the current basic program with the addition of pharmacological therapy, counseling, and follow-up. A Markov model was constructed that followed 65-year-old smokers with cancer over a lifetime horizon. Transition probabilities and mortality estimates were obtained from the published literature. Costs were obtained from standard costing sources in Ontario and reports. Probabilistic and deterministic sensitivity analyses were conducted to address parameter uncertainties. For smokers with cancer, the best practice smoking cessation program was more effective and more costly than the basic smoking cessation program. The incremental cost-effectiveness ratio of the best practice smoking cessation program compared to the basic smoking cessation program was $3367 per QALY gained and $5050 per LY gained for males, and $2050 per QALY gained and $4100 per LY gained for females. Results were most sensitive to the hazard ratio of mortality for former and current smokers, the probability of quitting smoking through participation in the program and smoking-attributable costs. The study results suggested that a best practice smoking cessation program could be a cost-effective option. These findings can support and guide implementation of smoking cessation programs.

AB - Quitting smoking after a diagnosis of cancer results in greater response to treatment and decreased risk of disease recurrence and second primary cancers. The objective of this study was to evaluate the potential cost-effectiveness of two smoking cessation approaches: the current basic smoking cessation program consisting of screening for tobacco use, advice, and referral; and a best practice smoking cessation program that includes the current basic program with the addition of pharmacological therapy, counseling, and follow-up. A Markov model was constructed that followed 65-year-old smokers with cancer over a lifetime horizon. Transition probabilities and mortality estimates were obtained from the published literature. Costs were obtained from standard costing sources in Ontario and reports. Probabilistic and deterministic sensitivity analyses were conducted to address parameter uncertainties. For smokers with cancer, the best practice smoking cessation program was more effective and more costly than the basic smoking cessation program. The incremental cost-effectiveness ratio of the best practice smoking cessation program compared to the basic smoking cessation program was $3367 per QALY gained and $5050 per LY gained for males, and $2050 per QALY gained and $4100 per LY gained for females. Results were most sensitive to the hazard ratio of mortality for former and current smokers, the probability of quitting smoking through participation in the program and smoking-attributable costs. The study results suggested that a best practice smoking cessation program could be a cost-effective option. These findings can support and guide implementation of smoking cessation programs.

KW - Cost-effectiveness

KW - Oncology

KW - Smoking cessation

UR - http://www.scopus.com/inward/record.url?scp=85050364077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050364077&partnerID=8YFLogxK

U2 - 10.1002/cam4.1495

DO - 10.1002/cam4.1495

M3 - Article

C2 - 30019421

AN - SCOPUS:85050364077

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

ER -